Oral delivery of gastro-resistant microencapsulated typhoid vaccine

References

• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. (2002). Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release, 79(1–3), 29–40.
   PubMed Web of Science ®Google Scholar
• Allaoui-Attarki K, Pecquet S, Fattal E, Trolle S, Chachaty E, Couvreur P, Andremont A. (1997). Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun, 65(3), 853–857.
   PubMed Web of Science ®Google Scholar
• Barrett TJ, Blake PA, Brown SL, Hoffman K, Llort JM, Feeley JC. (1983). Enzyme-linked immunosorbent assay for detection of human antibodies to Salmonella typhi Vi antigen. J Clin Microbiol, 17(4), 625–627.
   PubMed Web of Science ®Google Scholar
• Bejugam NK, Uddin AN, Gayakwad SG, D’Souza MJ. (2008). Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. J Microencapsul, 25(8), 577–583.
   PubMed Web of Science ®Google Scholar
• Carr KE, Hazzard RA, Reid S, Hodges GM. (1996). The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes. Pharm Res, 13(8), 1205–1209.
   PubMed Web of Science ®Google Scholar
• CDC. (1992). Health Information for International Travel. Atlanta: U.S. Department of Health and Human Services, Public Health Service.
   Google Scholar
• Challacombe SJ, Rahman D, O’Hagan DT. (1997). Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine, 15(2), 169–175.
   PubMed Web of Science ®Google Scholar
• Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. (2004). Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol, 10(12), 1769–1774.
   PubMed Web of Science ®Google Scholar
• Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cadé D. (2002). Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231(1), 83–95.
   PubMedGoogle Scholar
• Cripps AW, Kyd JM, Foxwell AR. (2001). Vaccines and mucosal immunisation. Vaccine, 19(17–19), 2513–2515.
   PubMed Web of Science ®Google Scholar
• Cumberland NS, St Clair Roberts J, Arnold WS, Patel RK, Bowker CH. (1992). Typhoid Vi: a less reactogenic vaccine. J Int Med Res, 20(3), 247–253.
   PubMed Web of Science ®Google Scholar
• Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27(8), 886–892.
   PubMed Web of Science ®Google Scholar
• Degussa. (2003). Enteric Coatings—pH Control with EUDRAGIT. (p. 8 ). Rohm Pharma Polymers.
   Google Scholar
• Degussa. (2005). Enteric coating of hard gelatin capsules with EUDRAGIT® 3.3.4e Page 1–3. Pharma Polymers.
   Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tic TR. (1990). Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release, 11(1–3), 205–214.
   Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM. (1991). Biodegradable microspheres as a vaccine delivery system. Mol Immunol, 28(3), 287–294.
   PubMed Web of Science ®Google Scholar
• Fegely KA, Simon BH, Rajabi-Siahboomi AR. (2006). Aqueous Enteric Coating Application on Non-Banded Hard Gelatin Capsules [AAPS Annual Meeting]. San Antonio, TX: The AAPS Journal, Poster # 2847.
   Google Scholar
• Ferry BL, Misbah SA, Stephens P, Sherrell Z, Lythgoe H, Bateman E, Banner C, Jones J, Groome N, Chapel HM. (2004). Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol, 136(2), 297–303.
   PubMed Web of Science ®Google Scholar
• Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LWJ, Williamson ED. (2002). Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun, 70(4), 2022–2088.
   PubMed Web of Science ®Google Scholar
• Galazka AM. (1993). Immunological basis for immunization. Module 1: General immunology. In Global Programme for Vaccines and Immunization EPoI (p. 13 ). Geneva: World Health Organization.
   Google Scholar
• Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. (2005). Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst, 22(5), 419–464.
   PubMed Web of Science ®Google Scholar
• Handler ES, Varsa EE, Gordon AS. (1966). Mechanisms of leukocyte production and release. V. Studies on the leukocytosis-inducing factor in the plasma of rats treated with typhoid-paratyphoid vaccine. J Lab Clin Med, 67(3), 398–410.
   PubMedGoogle Scholar
• Harvard-Apparatus. Mini Gelatin Drug Delivery Capsule. Last accessed May 23, 2008, at http://www.harvardapparatus.com/wcsstore/ConsumerDirect/images/site/hai/techdocs/BS4_B_42.pdf Last accessed 25 May 2008
   Google Scholar
• Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. (1996). Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm, 145(1–2), 231–240.
   Google Scholar
• Jones BE. (2009). Enteric coating of hard capsules, part 1. Tablets & Capsules, 10–14.
   Google Scholar
• Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. (1994). Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine, 12(3), 195–199.
   PubMed Web of Science ®Google Scholar
• Kramer PA. (1974). Letter: albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci, 63(10), 1646–1647.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (1996). Nanoparticles and microparticles for drug and vaccine delivery. J Anat, 189(Pt 3), 503–505.
   PubMed Web of Science ®Google Scholar
• Kyd J, Cripps A. (2000). Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. J Biotechnol, 83(1–2), 85–90.
   PubMed Web of Science ®Google Scholar
• Modi P, inventor, assignee. (1998). Drugs, Vaccines and Hormones in Polylactide Coated Microspheres. Canada. International publication # WO 95/22318 and International application # PCT/CA95/00074.
   Google Scholar
• O’Hagan DT. (1996). The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat, 189(Pt 3), 477–482.
   PubMedGoogle Scholar
• O’Hagan DT, McGee JP, Holmgren J, Mowat AM, Donachie AM, Mills KH, Gaisford W, Rahman D, Challacombe SJ. (1993). Biodegradable microparticles for oral immunization. Vaccine, 11(2), 149–154.
   PubMed Web of Science ®Google Scholar
• Park JH, Hong JJ, Choi ES, Lee JW. (2002). Efficacy of purified Vi polysaccharide typhoid vaccine. J Vet Sci, 3(2), 67–70.
   PubMedGoogle Scholar
• Pina ME, Sousa AT, Brojo AP. (1996). Enteric coating of hard gelatin capsules. Part 1. Application of hydroalcoholic solutions of formaldehyde in preparation of gastro-resistant capsules. Int J Pharma, 133(1–2), 139–148.
   Web of Science ®Google Scholar
• Pina ME, Sousa AT, Brojo AP. (1997). Enteric coating of hard gelatin capsules. Part 2—bioavailability of formaldehyde treated capsules. Int J Pharma, 148(1), 73–84.
   Web of Science ®Google Scholar
• Poskitt DC, Duffey K, Barnett J, Kimpton WG, Muller HK. (1984). The gut-associated lymphoid system of two species of Australian marsupial mice, Antechinus swainsonii and Antechinus stuartii. Distribution, frequency and structure of Peyer’s patches and lymphoid follicles in the small and large intestine. Aust J Exp Biol Med Sci, 62(Pt 1), 81–88.
   PubMedGoogle Scholar
• Seong SY, Cho NH, Kwon IC, Jeong SY. (1999). Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun, 67(7), 3587–3592.
   PubMed Web of Science ®Google Scholar
• Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. (1987). Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med, 166(5), 1510–1524.
   PubMed Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14(17–18), 1677–1685.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. (1996). Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res, 13(6), 896–901.
   PubMed Web of Science ®Google Scholar
• Typhim Vi®. (2005). Typhoid Vi Polysaccharide Vaccine (Typhim Vi®). Last accessed February 28, 2009, at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142811
   Google Scholar
• van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. (2001). Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer’s patches. Biomaterials, 22(7), 687–694.
   PubMed Web of Science ®Google Scholar
• Vivotif®. (2006). Typhoid Vaccine Live Oral Ty21a (Vivotif®). Last accessed February 28, 2009, at http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807
   Google Scholar
• Walker RI. (1994). New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine, 12(5), 387–400.
   PubMed Web of Science ®Google Scholar
• WHO. (2003). WHO Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever. Geneva: Switzerland.
   Google Scholar
• Yeboah KG, D’Souza MJ. (2009). Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul, 26(2), 166–179.
   PubMed Web of Science ®Google Scholar